Clinical trials: Body Weight Control
Obesity
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
- Trial name
- NCT00603902
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 4,008 people
- Sponsor
- Eisai Inc.
Chronic Management of Body Weight
Efficacy and Safety of HRS9531 Tablet in Obese Subjects
To evaluate the efficacy of HRS9531 tablet compared with placebo in reducing body weight in obese subjects after 26 weeks of treatment.
- Trial name
- NCT06841445
- Testing
- HRS9531 Tablet
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Type 2 Diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema.
- Trial name
- NCT06221969
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 197 sites in United States, Argentina and 6 more
- Volunteers
- 1,024 people
- Sponsor
- Novo Nordisk A/S
Obesity
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With Obesity
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with obesity. This study includes three multiple-ascending dose cohorts.
- Trial name
- NCT06951945
- Testing
- THDBH120 injection
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Type 2 Diabetes, Obesity
Japanese Single and Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic (PK) & Pharmacodynamic (PD) Study of AZD7687
This is a study in Japanese healthy volunteers to determine the safety and tolerability of the compound AZD7687. It will also assess how the body handles the drug and how it responds to the drug following single dose followed by…
- Trial name
- JSMAD (NCT01217905)
- Testing
- AZD7687
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin
The purpose of this study is to compare the efficacy (in terms of weight and hemoglobin type A1c [HbA1c]) and safety of topiramate (96 milligrams[mg] or 192 mg daily) with placebo in the treatment of obesity in Type 2 diabetic…
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231660
- Testing
- topiramate
- Volunteers
- 211 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112
1. Study Objective: The objective of this phase 1 clinical trial is to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and food effect of HSG4112 after oral administration in healthy male…
- Trial name
- NCT04732988
- Testing
- HSG4112
- Where
- 2 sites in South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Glaceum
Diabetes Type 2
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment
The purpose of this study is to compare the effectiveness of two different kinds of diabetes medications, insulin detemir (Levemir) and exenatide (Byetta), in improving blood sugar levels with little or no weight gain in patients…
- Trial name
- NCT01076842
- Testing
- Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Novo Nordisk A/S
Obese Adolescents, Obesity
A Study of XW003 Injection in Chinese Adolescents With Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XW003 injection in Chinese adolescents with obesity
- Trial name
- NCT07143227
- Testing
- XW003 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- AURORA-1 (NCT07743463)
- Testing
- ASC30 tablets A1
- Where
- 122 sites in United States, Canada and 5 more
- Volunteers
- 3,003 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Overweight
Efficacy and Safety of Zenoctil in Reducing Body Weight
The intention of the study is to evaluate the safety and potential body weight and body fat loss effects of a 12-week treatment with Zenoctil in a randomized, double-blind, placebo-controlled, parallel study conducted in…
- Trial name
- NCT01423617
- Testing
- Zenoctil
- Where
- Germany
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss.
- Trial name
- TRIUMPH-6 (NCT06859268)
- Testing
- Retatrutide
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 643 people
- Sponsor
- Eli Lilly and Company
Heart Failure
Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants
A research study that involves the use of an investigational drug called THRV-1268. The main purpose is to measure the safety (whether it causes any side effects) and tolerability (if it does cause any side effects, how well your…
- Trial name
- NCT07186946
- Testing
- THRV-1268
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Thryv Therapeutics, Inc.
Overweight, Obesity
Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes
This study will asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.
- Trial name
- NCT02307279
- Testing
- Gelesis100
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 436 people
- Sponsor
- Gelesis, Inc.
Overweight, Obesity
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.
- Trial name
- NCT00392925
- Testing
- pramlintide acetate 360 mcg, metreleptin, Pramlintide acetate 180 mcg
- Where
- 12 sites in United States
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
Liver Fat, Liver Fibrosis
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease…
- Conditions
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes
- Trial name
- Ertu-NASH (NCT05644717)
- Testing
- Ertugliflozin 5 mg, 15mg
- Where
- Pakistan
- Volunteers
- 164 people
- Sponsor
- Getz Pharma
Overweight and Obesity
Efficacy and Safety of Glucosanol™ in Body Weight Reduction
It was proven in a previous clinical study that Glucosanol™ is effective and safe in reducing weight in the overweight and obese.
- Trial name
- NCT02930668
- Testing
- Glucosanol 350mg, Glucosanol 500mg
- Where
- Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Height, Cognitive Function
A Study to Evaluate the Effects of a Dietary Supplement on Children's Health and Development Outcomes.
A 6-month virtual two-armed randomized double-blind placebo-controlled clinical trial. Participants will take NuBest Tall Growth Protein Powder or a placebo daily.
- Conditions
- Height, Cognitive Function, Weight Gain
- Trial name
- NCT06704178
- Testing
- NuBest Tall Growth Protein Powder
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- NuBest
Cannabis Use, Cachexia; Cancer
Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
A large number of patients with advanced cancer also suffer from cachexia. Cachexia is a syndrome characterized by loss of skeletal muscle mass (with/or without loss of fat mass) that cannot be reversed by nutritional support and…
- Conditions
- Cannabis Use, Cachexia; Cancer, Advanced Cancer
- Trial name
- SERENITY (NCT04001010)
- Testing
- PPP011
- Where
- Canada
- Volunteers
- 334 people
- Sponsor
- Tetra Bio-Pharma
Obstructive Sleep Apnea (OSA) and Obesity
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy
This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity not receiving positive airway pressure (PAP)…
- Trial name
- NCT07787260
- Testing
- HDM1005
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.